FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086146987> ?p ?o ?g. }

• W3086146987 endingPage "700" @default.
• W3086146987 startingPage "693" @default.
• W3086146987 abstract "Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited.To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting.This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded.Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P < 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P < 0.0001 and P < 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1).Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies." @default.
• W3086146987 created "2020-09-21" @default.
• W3086146987 creator A5003045874 @default.
• W3086146987 creator A5010184369 @default.
• W3086146987 creator A5012727285 @default.
• W3086146987 creator A5014762006 @default.
• W3086146987 creator A5017788164 @default.
• W3086146987 creator A5021496401 @default.
• W3086146987 creator A5026673851 @default.
• W3086146987 creator A5035425594 @default.
• W3086146987 creator A5049568970 @default.
• W3086146987 creator A5053176930 @default.
• W3086146987 creator A5055899118 @default.
• W3086146987 creator A5058977009 @default.
• W3086146987 creator A5063944820 @default.
• W3086146987 creator A5064829159 @default.
• W3086146987 creator A5069693351 @default.
• W3086146987 creator A5072653864 @default.
• W3086146987 creator A5079774561 @default.
• W3086146987 creator A5085751204 @default.
• W3086146987 creator A5087192032 @default.
• W3086146987 creator A5088206921 @default.
• W3086146987 date "2020-10-13" @default.
• W3086146987 modified "2023-09-26" @default.
• W3086146987 title "Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience" @default.
• W3086146987 cites W1980055161 @default.
• W3086146987 cites W1980883233 @default.
• W3086146987 cites W1993273784 @default.
• W3086146987 cites W2021018799 @default.
• W3086146987 cites W2033881749 @default.
• W3086146987 cites W2036659843 @default.
• W3086146987 cites W2047354818 @default.
• W3086146987 cites W2050172669 @default.
• W3086146987 cites W2067327580 @default.
• W3086146987 cites W2079598877 @default.
• W3086146987 cites W2080165152 @default.
• W3086146987 cites W2096991001 @default.
• W3086146987 cites W2127834887 @default.
• W3086146987 cites W2145834141 @default.
• W3086146987 cites W2276035339 @default.
• W3086146987 cites W2326643498 @default.
• W3086146987 cites W2587818680 @default.
• W3086146987 cites W2591245715 @default.
• W3086146987 cites W2730335164 @default.
• W3086146987 cites W2735708380 @default.
• W3086146987 cites W2789656381 @default.
• W3086146987 cites W2802931074 @default.
• W3086146987 cites W2899985300 @default.
• W3086146987 cites W2944333492 @default.
• W3086146987 cites W2948260386 @default.
• W3086146987 cites W2957382343 @default.
• W3086146987 cites W2972256509 @default.
• W3086146987 cites W2981214845 @default.
• W3086146987 cites W2985489166 @default.
• W3086146987 cites W2999046156 @default.
• W3086146987 cites W3003568793 @default.
• W3086146987 cites W3004526292 @default.
• W3086146987 cites W3005356559 @default.
• W3086146987 cites W3012169661 @default.
• W3086146987 cites W4292528167 @default.
• W3086146987 doi "https://doi.org/10.1111/jdv.16931" @default.
• W3086146987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32916767" @default.
• W3086146987 hasPublicationYear "2020" @default.
• W3086146987 type Work @default.
• W3086146987 sameAs 3086146987 @default.
• W3086146987 citedByCount "21" @default.
• W3086146987 countsByYear W30861469872021 @default.
• W3086146987 countsByYear W30861469872022 @default.
• W3086146987 countsByYear W30861469872023 @default.
• W3086146987 crossrefType "journal-article" @default.
• W3086146987 hasAuthorship W3086146987A5003045874 @default.
• W3086146987 hasAuthorship W3086146987A5010184369 @default.
• W3086146987 hasAuthorship W3086146987A5012727285 @default.
• W3086146987 hasAuthorship W3086146987A5014762006 @default.
• W3086146987 hasAuthorship W3086146987A5017788164 @default.
• W3086146987 hasAuthorship W3086146987A5021496401 @default.
• W3086146987 hasAuthorship W3086146987A5026673851 @default.
• W3086146987 hasAuthorship W3086146987A5035425594 @default.
• W3086146987 hasAuthorship W3086146987A5049568970 @default.
• W3086146987 hasAuthorship W3086146987A5053176930 @default.
• W3086146987 hasAuthorship W3086146987A5055899118 @default.
• W3086146987 hasAuthorship W3086146987A5058977009 @default.
• W3086146987 hasAuthorship W3086146987A5063944820 @default.
• W3086146987 hasAuthorship W3086146987A5064829159 @default.
• W3086146987 hasAuthorship W3086146987A5069693351 @default.
• W3086146987 hasAuthorship W3086146987A5072653864 @default.
• W3086146987 hasAuthorship W3086146987A5079774561 @default.
• W3086146987 hasAuthorship W3086146987A5085751204 @default.
• W3086146987 hasAuthorship W3086146987A5087192032 @default.
• W3086146987 hasAuthorship W3086146987A5088206921 @default.
• W3086146987 hasConcept C126322002 @default.
• W3086146987 hasConcept C159110408 @default.
• W3086146987 hasConcept C16005928 @default.
• W3086146987 hasConcept C167135981 @default.
• W3086146987 hasConcept C197934379 @default.
• W3086146987 hasConcept C23131810 @default.
• W3086146987 hasConcept C2776173921 @default.
• W3086146987 hasConcept C2777011040 @default.

• next